Insulin's Evolution: Profit vs. Patient Care

This chapter explores the historical transition from animal-derived insulin to recombinant human insulin, emphasizing the marketing claims that fueled its adoption despite limited evidence of superiority. It highlights the impact of pharmaceutical pricing strategies, ethical dilemmas in drug development, and the complex influence of corporate interests on medical practices. The discussion calls for greater transparency and regulatory reforms to ensure patient care isn't overshadowed by profit motives.